First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Journal of Translational Medicine
Linda M LiauMarnix L Bosch

Abstract

Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly diagnosed glioblastoma. After surgery and chemoradiotherapy, patients were randomized (2:1) to receive temozolomide plus DCVax-L (n = 232) or temozolomide and placebo (n = 99). Following recurrence, all patients were allowed to receive DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); the secondary endpoint was overall survival (OS). For the intent-to-treat (ITT) population (n = 331), median OS (mOS) was 23.1 months from surgery. Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L. For patients with methylated MGMT (n = 131), mOS was 34.7 months from surgery, with a 3-year survival of 46.4%. As of this analysis, 223 patients are ≥ 30 months past their surgery date; 67 of these (30.0%) have lived ≥ 30 months and have a Kaplan-Meier (KM)-derived mOS of 46.5 months. 182 patients are ≥ 36 months past surgery; 44 of these (24.2%) have lived ≥ 36 months and have a KM-derived mOS of 88.2 months. A population of extended survivors (n = 100...Continue Reading

References

Sep 9, 2004·Frontiers in Bioscience : a Journal and Virtual Library·Robert M Prins, Linda M Liau
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Linda M LiauMichael D Roth
Dec 21, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Robert M PrinsLinda M Liau
Aug 2, 2008·The New England Journal of Medicine·Robert M PrinsLinda M Liau
Sep 6, 2008·Science·D Williams ParsonsKenneth W Kinzler
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang WickHoward A Fine
Oct 16, 2010·Journal of Translational Medicine·Michelle J HickeyCarol A Kruse
Dec 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert M PrinsLinda M Liau
Mar 23, 2012·Nature Reviews. Cancer·Karolina Palucka, Jacques Banchereau
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy T BatchelorMartin van den Bent
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Jan 27, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Manfred WestphalTorsten Pietsch
Oct 21, 2015·Journal of the National Comprehensive Cancer Network : JNCCN·Stuart A GrossmanXiaobu Ye
Dec 17, 2015·JAMA : the Journal of the American Medical Association·Roger StuppZvi Ram
Jul 28, 2016·Cancer Biology & Medicine·Samuel J HarrisTimothy A Yap
Aug 9, 2017·Current Treatment Options in Oncology·Russell MaxwellMichael Lim

❮ Previous
Next ❯

Citations

Oct 13, 2018·Current Treatment Options in Oncology·Lan B Hoang-Minh, Duane A Mitchell
Mar 12, 2019·Frontiers in Oncology·Karishma R RajaniTerry C Burns
Apr 30, 2019·Frontiers in Immunology·Beatris Mastelic-GavilletLana E Kandalaft
Oct 28, 2019·Oncoimmunology·Jenny SprootenAbhishek D Garg
Oct 8, 2019·British Journal of Hospital Medicine·Edmund Watson, Robert Danby
Dec 7, 2019·Nature Reviews. Cancer·John H SampsonDavid M Ashley
Mar 25, 2020·Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko·I V ChekhoninO I Gurina
Jun 9, 2020·Frontiers in Immunology·Alycia GardnerBrian Ruffell
Jul 11, 2020·Pathology Oncology Research : POR·Ágnes DobiKatalin Hideghéty
Aug 1, 2020·Current Treatment Options in Oncology·Ashley P GhiaseddinDavid D Tran
Oct 31, 2018·Frontiers in Oncology·Kewal K Jain
Jun 29, 2018·Expert Opinion on Therapeutic Patents·Matthew HarrisDavid Bailey
Dec 21, 2018·Frontiers in Oncology·John LynesEdjah Nduom
Sep 28, 2018·Nature·Michael Eisenstein
Apr 20, 2019·Journal for Immunotherapy of Cancer·Kalijn F BolI Jolanda M de Vries
Feb 23, 2020·Cancer Immunology, Immunotherapy : CII·Qian-Ting WangYou-Wen He
Apr 9, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Á Rodríguez PérezD Benítez-Ribas
Apr 10, 2020·Topics in Magnetic Resonance Imaging : TMRI·Stephen J BagleyDonald M O'Rourke
Oct 6, 2020·Neuro-oncology Practice·Megan L MontoyaHideho Okada
Oct 18, 2018·Frontiers in Immunology·Wouter W van WilligenKalijn F Bol
Aug 23, 2019·Bone Marrow Transplantation·Ana Marcu, Matthias Eyrich
Oct 11, 2019·Drugs·Rimas V LukasAdam M Sonabend
Nov 19, 2019·Frontiers in Immunology·Jitka FucikovaRadek Spisek
Jun 2, 2020·CA: a Cancer Journal for Clinicians·Aaron C TanMustafa Khasraw
May 24, 2020·Current Neurology and Neuroscience Reports·Elisa K LiuSylvia C Kurz
Sep 29, 2020·Japanese Journal of Clinical Oncology·Takahide NejoHideho Okada
Jul 29, 2020·Cancer Reports·Stephen LoweAdriana Olar
Apr 8, 2020·Journal of Neuro-oncology·Ravi MedikondaMichael Lim
Feb 23, 2019·Current Treatment Options in Oncology·Tresa McGranahanSeema Nagpal

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
leukapheresis
biopsy

Software Mentioned

SAS

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.